Ablynx appoints new commercial head
This article was originally published in Scrip
Ghent, Belgium-based Ablynx, a biopharmaceutical company developing nanobodies, has named Johan Heylen chief commercial officer. He will assume responsibility for all Ablynx's commercial activities and has more than 20 years of experience in global biopharmaceutical sales, marketing and business development at GlaxoSmithKline, Servier and Wyeth. Most recently, Mr Heylen was executive director, global commercial lead of cancer immunotherapeutics at GSK.